In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?

Executive Summary

Cardiologists and interventionalists continue to disagree on the importance of the COURAGE trial results. Academic disputes aside, the question for industry is whether this study will further drive down stent usage.
Advertisement

Related Content

Another Call for Better Risk Stratification in Cardiac Imaging
CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena
Top Device Stories of the Decade
AHA Highlights: Improving Patient Care
Trends for the New Year: Can Medtech Build on the Success of 2007?
TCT Debates Cardiology's "Climate of Calamity"
ESC Highlights: DES Debate Continues, Hybrid-Imaging Hot Ticket
Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Behind the DES Debate: A New Model for Device Development?
COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel